Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Neoplasms 4Lung Neoplasms 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Rectal Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Unresectable Non-small Cell Lung Cancer 1Tobacco Use Cessation 1Recurrence 1Rectal Diseases 1Pancreatic Cancer Liver Metastases 1Ovarian Neoplasms 1Ototoxicity 1Neoplasms, Second Primary 1Neoplasms by Site 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma 1Intestinal Neoplasms 1Intestinal Diseases 1Hodgkin Disease 1Hearing Loss 1HER2 Positive Metastatic Breast Cancer 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1

Interventions

endostar protein 1Surgical Procedures, Operative 1Endostatins 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Unresectable Non-small Cell Lung Cancer × Drug Therapy × Clear all
NCT06617936 2025-07-15

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Shandong Public Health Clinical Center

Phase 2 Recruiting
36 enrolled
Thoracic

Unresectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡